Table 4.
miR-125b overexpression comparisons in participants with polyposis.
| miR-125b Overexpression: | No | Yes | p |
|---|---|---|---|
| (n = 41) | (n = 45) | ||
| Age (years), median (IQR) | 50 (44–61) | 46 (36–55) | 0.073 |
| Sex (F), nr (%) | 18 (43.9) | 11 (24.44) | 0.057 |
| Smoking (Yes), nr (%) | 11 (26.83) | 9 (20) | 0.454 |
| Allergy (Yes), nr (%) | 15 (36.59) | 17 (37.78) | 0.909 |
| Allergy type, nr (%) | 0.187 | ||
| NSAIDs | 4 (9.76) | 10 (22.22) | |
| Environmental | 11 (26.83) | 7 (15.56) | |
| No | 26 (63.41) | 28 (62.22) | |
| Asthma (Yes), nr (%) | 12 (29.27) | 16 (35.56) | 0.534 |
| Endoscopy score average score, median (IQR) | 2 (1.5–2.5) | 2.5 (2–3) | 0.021 |
| Endoscopy score maxim score, median (IQR) | 2 (2–3) | 3 (2–3) | 0.027 |
| Endoscopy score sum score, median (IQR) | 4 (3–5) | 5 (4–6) | 0.021 |
| Eosinophiles (%), median (IQR) | 6.42 (5.62–7.29) | 8.37 (6.54–11.09) | 0.018 |
| PHQ-9 preop, median (IQR) | 4 (2–6) | 5 (3–8) | 0.107 |
| Lund Mackay sum score, median (IQR) | 15 (13–19) | 17 (14–20) | 0.063 |
| SNOT initial, median (IQR) | 36 (26–54) | 49 (28–65) | 0.093 |
SD, standard deviation; IQR, interquartile range; CI, confidence interval; NSAIDs, nonsteroidal anti-inflamatory drugs; PHQ-9 Depression test questionnaire; SNOT-22, Sinonasal outcome test; miR, micro-ribonucleic acid.